For the Inventor, By the Inventor

Enter assignee name

Belmont, MA, United States of America

The Mclean Hospital Corporation

USPTO Granted Patents = 123

CIPO Patents = 4

EPO Patents = 17

Trademarks = 11

Forward Citations = 1,638

Loading Chart...

Loading Chart...

121 inventors (with patents filed for the assignee):

Perry F Renshaw (21 out of 27 patents)

Martin H Teicher (14 out of 19 patents)

Ole Isacson (10 out of 10 patents)

4. Kwang-Soo Kim (9 out of 9 patents)

5. John L Neumeyer (9 out of 20 patents)

6. Michael L Rohan (9 out of 11 patents)

7. Steven Bradley Lowen (8 out of 9 patents)

8. Ralph A Nixon (8 out of 11 patents)

9. Bruce M Cohen (6 out of 7 patents)

10. Aimee Parow (6 out of 6 patents)

11. Scott E Lukas (6 out of 6 patents)

12. Richard N Blazey (6 out of 35 patents)

13. David Lynn Patton (6 out of 204 patents)

14. Paige Miller (5 out of 11 patents)

15. Luis C Maas, Iii (5 out of 5 patents)

Core Competencies:

Muscarinic Antagonists

GABAergic Interneurons

Genome-Nonintegrating Reprogramming

Glucocerebrosidase Gene Therapy

Cerebral Blood Flow Tracking

Antisense Compounds

Dopaminergic Neurons

Mitochondrial Replacement Therapy

Magnetic Field Stimulation

Psychiatric Disorders Treatment

Attention Deficit Hyperactivity Disorder

Cluster Headache Disorders

123 patents: Sort by Forward Citations

1. 12396988 - Methods of using muscarinic antagonists in the treatment of depression (2025-08-26),

2. 12241084 - Methods for efficient generation of GABAergic interneurons from pluripotent stem cells (2025-03-04),

3. 11898169 - Synergistic genome-nonintegrating reprogramming by microRNAs and transcription factors (2024-02-13),

4. 11767507 - Methods for efficient generation of GABAergic interneurons from pluripotent stem cells (2023-09-26),

5. 11026943 - Aminoquinoline derivatives and uses thereof (2021-06-08),

6. 11001809 - Synergistic genome-nonintegrating reprogramming by microRNAs and transcription factors (2021-05-11),

7. 10967073 - Glucocerebrosidase gene therapy for Parkinson's disease (2021-04-06),

8. 10912470 - System and method for tracking cerebral blood flow in fMRI (2021-02-09),

9. 10787669 - Antisense compounds targeting Leucine-Rich repeat kinase 2(LRRK2) for the treatment of Parkinsons disease (2020-09-29),

10. 10720242 - Systems and methods for modeling and predicting effective treatments for schizophrenia and other disorders (2020-07-21),

11. 10426969 - Magnetic field stimulation (2019-10-01),

12. 10370667 - Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease (2019-08-06),

13. 10201314 - System and method for evaluation of circulatory function (2019-02-12),

14. 10085642 - Multi-modal imaging of blood flow (2018-10-02),

15. 10081600 - 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof (2018-09-25),

The McLean Hospital Corporation is a renowned psychiatric hospital in Belmont, Massachusetts, United States. It is the largest psychiatric hospital of Harvard Medical School and consistently ranks among the best hospitals for psychiatric care in the nation. McLean Hospital provides a comprehensive range of mental health services, including inpatient and outpatient programs, research, and education. With a dedicated team of professionals, McLean Hospital aims to improve the lives of individuals struggling with mental health disorders through compassionate care and innovative treatments.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

123 Patents

#1 in Belmont, MA

#170 in Massachusetts

#3,028 in US

#6,321 in the World

Belmont, MA, United States of America

The Mclean Hospital Corporation

Forward Citations = 1,638

121 inventors:

Perry F Renshaw (21 out of 27 patents)

Martin H Teicher (14 out of 19 patents)

Ole Isacson (10 out of 10 patents)

4. Kwang-Soo Kim (9 out of 9 patents)

5. John L Neumeyer (9 out of 20 patents)

Please report any incorrect information to support@idiyas.com

Loading…